everlinQ endoAVF Post Market Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 100 participants.

Also called NCT02682420

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
  • C. R. Bard Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02682420
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada, Germany, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02682420. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2019-08 (actual). Results posted on 2021-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
everlinQ endoAVF Post Market Study
Intervention (Device)
everlinQ endoAVF System
Lead sponsor
C. R. Bard (class: industry)

Record details

Record id
cardio:ct-nct02682420
Content hash
a1919fb456d9571887b719c28029f5cb058025634ad1f68ecff2769e47e37dbf